Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alkermes

EDT merger boosts revenues

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes

4Q Revenues: $130.5 million (+155%)

4Q Loss: $63.4 million (loss of $13.1 million 4Q11)

FY Revenues: $390.0 million (+109%)

FY Loss: $113.7 million (loss of $45.5 million FY11)

Comments: Manufacturing and royalty revenues were $326.4 million for the year (+108%). Product sales were $41.2 million (+43%), and R&D revenue was $22.3 million compared to $880,000 FY11. Growth in the quarter and FY reflects the Elan Drug Technologies merger. Results include a charge of $45.8 million related to in-process R&D acquired in the merger.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters